Skip to main content
. Author manuscript; available in PMC: 2022 Oct 14.
Published in final edited form as: Cell. 2021 Sep 27;184(21):5465–5481.e16. doi: 10.1016/j.cell.2021.09.005

Figure 4. A combination of NEUROD1 and DLX2 fails to convert striatal astrocytes.

Figure 4.

(A) A schematic illustration of the Cre-FLEX system.

(B) Study design to examine AtN conversion in the striatum. Astrocytes were traced with YFP after Tamoxifen treatments.

(C) Confocal images of the indicated markers. Scales, 50 μm.

(D) Quantifications showing a lack of YFP-traced mCherry+ neurons (n = 4 mice per group; mean ± SEM; ****p < 0.0001).

(E) Study design to examine AtN conversion in the striatum. Astrocytes were constitutively traced with YFP.

(F) Confocal images of the indicated markers. Scales, 50 μm.

(G) Quantifications showing a lack of YFP-traced mCherry+ neurons (n = 4 mice per group; mean ± SEM; ****p < 0.0001).

(H) Study design to examine NEUROD1 and DLX2 expression.

(I) Confocal images of the indicated markers. DLX2 expression is indicated by the HA staining. Scales, 50 μm.

(J) Quantifications showing robust expression of NEUROD1 and DLX2 (indicated by HA) in mCherry+ cells (n = 3 mice per group; mean ± SEM).

See also Figure S5.